Brintellix Label Gives Lundbeck Ground For Tolerability Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
Lundbeck/Takeda’s newly approved antidepressant Brintellix is poised to enter the crowded, genericized antidepressant market at the end of 2013. Potential advantages in labeling include flexible dosing, lack of weight gain and lower rates of sexual dysfunction compared to some other drugs.
You may also be interested in...
Brintellix Review To Focus On Cognitive Function Measurement
Takeda's request for novel claim for an antidepressant hinges on FDA acceptance of clinical outcomes assessment used in vortioxetine's trials, but agency raises doubts about utility of results.
Europe’s CHMP Clears Just Two Drugs: Brintellix And Opsumit
Positive opinions for new medicines were relatively scarce in Europe this month, with only Lundbeck's new antidepressant, Brintellix and Actelion's PAH therapy, Opsumit, being recommended for approval.
Takeda Aims To Turn Brintellix Into CNS Cornerstone, Arm-In-Arm With Lundbeck
Multimodal antidepressant Brintellix (vortioxetine) represents Takeda’s first shot at a major depression launch and the future for Lundbeck as blockbuster Lexapro fades into the distance. Time will tell if the partners have what it takes to compete in a highly genericized market; evidence of cognitive benefits could help.